Brolucizumab-dbll 120 mg/ML
RxNorm 2204917

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2204917 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: brolucizumab-dbll 120 mg/ML.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDC
Brolucizumab-dbll 120 mg/ML
AUI:11455458
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDCPrescribable

Semantic Clinical Drug Component (SCDC):
Brolucizumab-dbll 120 mg/ML
(Atom ID: 11455458)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
brolucizumab-dbll 120 MG/ML
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2204917
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11455458
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDC
Semantic Clinical Drug Component (Ingredient + Strength)
Source Code
2204917
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BOSS STRENGTH DENOM UNIT
ML
RXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE
1
RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNIT
MG
RXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE
120
RXN Boss Strength Num Value
RXN IN EXPRESSED FLAG
P
Strength Expressed As Precise Flag
RXN STRENGTH
120 MG/ML
Strength plus unit of SCDC

Patient Education

Brolucizumab-dbll Injection


Brolucizumab-dbll injection is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Brolucizumab-dbll is in a class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss.
[Learn More]


* Please review the disclaimer below.